Vertex Pharmaceuticals Incorporated Stock price

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:05:50 2024-03-28 pm EDT 5-day change 1st Jan Change
417.3 USD +0.00% Intraday chart for Vertex Pharmaceuticals Incorporated +0.68% +2.86%
Sales 2024 * 10.73B Sales 2025 * 11.74B Capitalization 108B
Net income 2024 * 3.9B Net income 2025 * 4.5B EV / Sales 2024 * 8.45 x
Net cash position 2024 * 17.11B Net cash position 2025 * 21.54B EV / Sales 2025 * 7.35 x
P/E ratio 2024 *
27.8 x
P/E ratio 2025 *
24.1 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.89%
More Fundamentals * Assessed data
Dynamic Chart
Vertex Pharmaceuticals Gets FDA Approval for VX-407's Investigational New Drug Application to Treat Kidney Disease MT
Vertex Gets FDA OK to Study VX-407 in Genetic Kidney Disease DJ
Vertex Pharmaceuticals Incorporated Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease CI
Transcript : Vertex Pharmaceuticals Incorporated Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 04:00 PM
Transcript : Vertex Pharmaceuticals Incorporated Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM
Vertex Pharmaceuticals Insider Sold Shares Worth $2,142,974, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $506,546, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,519,637, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Gets Positive Opinion for Kalydeco From European Medicines Agency to Treat Cystic Fibrosis MT
Vertex Pharmaceuticals Cystic Fibrosis Drug Gets Positive Opinion in EU For Treatment in Infants DJ
Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older CI
Prices for new US drugs rose 35% in 2023, more than the previous year RE
RBC Trims Price Target on Vertex Pharmaceuticals to $417 From $420, Keeps Sector Perform Rating MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,776,528, According to a Recent SEC Filing MT
Wolfe Research Initiates Vertex Pharmaceuticals With Outperform Rating, $515 Price Target MT
More news
1 day+0.63%
1 week+1.01%
Current month-0.20%
1 month-1.65%
3 months+2.60%
6 months+19.12%
Current year+3.20%
More quotes
1 week
412.19
Extreme 412.19
420.67
1 month
406.97
Extreme 406.97
433.99
Current year
403.43
Extreme 403.43
448.40
1 year
310.90
Extreme 310.9
448.40
3 years
176.36
Extreme 176.36
448.40
5 years
163.68
Extreme 163.681
448.40
10 years
59.79
Extreme 59.79
448.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 17-01-31
Chairman 68 09-07-07
Director of Finance/CFO 55 19-04-09
Members of the board TitleAgeSince
Director/Board Member 68 17-06-07
Chairman 68 09-07-07
Director/Board Member 64 97-12-31
More insiders
Date Price Change Volume
24-03-28 418.5 +0.28% 418 972
24-03-27 417.3 -0.27% 905,446
24-03-26 418.5 +0.58% 952,561
24-03-25 416 +0.09% 732,827
24-03-22 415.7 -0.01% 821,734

Delayed Quote Nasdaq, March 28, 2024 at 10:55 am EDT

More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
417.3 USD
Average target price
459.7 USD
Spread / Average Target
+10.16%
Consensus
  1. Stock
  2. Equities
  3. Stock Vertex Pharmaceuticals Incorporated - Nasdaq